Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 13 entries
Sorted by: Best Match Show Resources per page
Improved uptake and retention of lipophilic prodrug to improve treatment of HIV.

Advanced drug delivery reviews

Yatvin MB, Li W, Meredith MJ, Shenoy MA.
PMID: 10837773
Adv Drug Deliv Rev. 1999 Oct 18;39(1):165-182. doi: 10.1016/s0169-409x(99)00025-3.

Dideoxynucleosides currently in use for anti-HIV therapy have been found to be inefficient in passing through the blood-brain barrier to enter and maintain therapeutic drug levels in brain, a very significant reservoir of HIV. The low bioavailability of these...

Cite
Yatvin MB, Li W, Meredith MJ, et al. Improved uptake and retention of lipophilic prodrug to improve treatment of HIV. Adv Drug Deliv Rev. 1999;39(1):165-182doi: 10.1016/s0169-409x(99)00025-3.
Yatvin, M. B., Li, W., Meredith, M. J., & Shenoy, M. A. (1999). Improved uptake and retention of lipophilic prodrug to improve treatment of HIV. Advanced drug delivery reviews, 39(1), 165-182. https://doi.org/10.1016/s0169-409x(99)00025-3
Yatvin, et al. "Improved uptake and retention of lipophilic prodrug to improve treatment of HIV." Advanced drug delivery reviews vol. 39,1 (1999): 165-182. doi: https://doi.org/10.1016/s0169-409x(99)00025-3
Yatvin MB, Li W, Meredith MJ, Shenoy MA. Improved uptake and retention of lipophilic prodrug to improve treatment of HIV. Adv Drug Deliv Rev. 1999 Oct 18;39(1):165-182. doi: 10.1016/s0169-409x(99)00025-3. PMID: 10837773.
Copy Download .nbib Format: NLM
Flow-injection spectrophotometric determination of reverse transcriptase inhibitors used for acquired immuno deficiency syndrome (AIDS) treatment: focus on strategies for dealing with the background components.

Analytica chimica acta

Checa A, Oliver R, Saurina J, Hernández-Cassou S.
PMID: 17723473
Anal Chim Acta. 2006 Jul 14;572(1):155-64. doi: 10.1016/j.aca.2006.05.041. Epub 2006 May 20.

This paper describes a rapid method for the quantification of reverse transcriptase inhibitors in mixtures of therapeutic interest containing zidovudine, zalcitabine and nevirapine. The method is based on a pH-gradient flow-injection system with diode array detection and further data...

Cite
Checa A, Oliver R, Saurina J, et al. Flow-injection spectrophotometric determination of reverse transcriptase inhibitors used for acquired immuno deficiency syndrome (AIDS) treatment: focus on strategies for dealing with the background components. Anal Chim Acta. 2006;572(1):155-64doi: 10.1016/j.aca.2006.05.041.
Checa, A., Oliver, R., Saurina, J., & Hernández-Cassou, S. (2006). Flow-injection spectrophotometric determination of reverse transcriptase inhibitors used for acquired immuno deficiency syndrome (AIDS) treatment: focus on strategies for dealing with the background components. Analytica chimica acta, 572(1), 155-64. https://doi.org/10.1016/j.aca.2006.05.041
Checa, Antonio, et al. "Flow-injection spectrophotometric determination of reverse transcriptase inhibitors used for acquired immuno deficiency syndrome (AIDS) treatment: focus on strategies for dealing with the background components." Analytica chimica acta vol. 572,1 (2006): 155-64. doi: https://doi.org/10.1016/j.aca.2006.05.041
Checa A, Oliver R, Saurina J, Hernández-Cassou S. Flow-injection spectrophotometric determination of reverse transcriptase inhibitors used for acquired immuno deficiency syndrome (AIDS) treatment: focus on strategies for dealing with the background components. Anal Chim Acta. 2006 Jul 14;572(1):155-64. doi: 10.1016/j.aca.2006.05.041. Epub 2006 May 20. PMID: 17723473.
Copy Download .nbib Format: NLM
In vitro studies of the toxicity of nucleoside analogues used in the treatment of HIV infection.

Toxicology in vitro : an international journal published in association with BIBRA

Flint OP.
PMID: 20692986
Toxicol In Vitro. 1994 Aug;8(4):677-83. doi: 10.1016/0887-2333(94)90042-6.

The nucleoside analogues, 3'-azido-3'-deoxythymidine (AZT, zidovudine), 2',3'-dideoxyinosine (ddI, didanosine) and 2',3'-dideoxycytidine (ddC, zalcitabine), used in the treatment of human immunodeficiency virus (HIV) infection, have been associated with a number of dose-limiting toxicities in clinical studies. These include myelotoxicity (AZT),...

Cite
Flint OP. In vitro studies of the toxicity of nucleoside analogues used in the treatment of HIV infection. Toxicol In Vitro. 1994;8(4):677-83doi: 10.1016/0887-2333(94)90042-6.
Flint, O. P. (1994). In vitro studies of the toxicity of nucleoside analogues used in the treatment of HIV infection. Toxicology in vitro : an international journal published in association with BIBRA, 8(4), 677-83. https://doi.org/10.1016/0887-2333(94)90042-6
Flint, O P. "In vitro studies of the toxicity of nucleoside analogues used in the treatment of HIV infection." Toxicology in vitro : an international journal published in association with BIBRA vol. 8,4 (1994): 677-83. doi: https://doi.org/10.1016/0887-2333(94)90042-6
Flint OP. In vitro studies of the toxicity of nucleoside analogues used in the treatment of HIV infection. Toxicol In Vitro. 1994 Aug;8(4):677-83. doi: 10.1016/0887-2333(94)90042-6. PMID: 20692986.
Copy Download .nbib Format: NLM
Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010.

AIDS research and treatment

Sepúlveda-Torres Ldel C, De La Rosa A, Cumba L, Boukli N, Ríos-Olivares E, Cubano LA.
PMID: 22593823
AIDS Res Treat. 2012;2012:934041. doi: 10.1155/2012/934041. Epub 2012 Apr 24.

This is a continuation of our efforts to maintain a record of the evolution of HIV-1 infection in Puerto Rico by monitoring the expression levels of antiretroviral drug-resistance-associated mutations. Samples from 2,500 patients from 2006-2010 were analyzed using the...

Cite
Sepúlveda-Torres Ldel C, De La Rosa A, Cumba L, et al. Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010. AIDS Res Treat. 2012;2012:934041doi: 10.1155/2012/934041.
Sepúlveda-Torres, L. d. e. l. . C., De La Rosa, A., Cumba, L., Boukli, N., Ríos-Olivares, E., & Cubano, L. A. (2012). Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010. AIDS research and treatment, 2012934041. https://doi.org/10.1155/2012/934041
Sepúlveda-Torres, Lycely Del C, et al. "Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010." AIDS research and treatment vol. 2012 (2012): 934041. doi: https://doi.org/10.1155/2012/934041
Sepúlveda-Torres Ldel C, De La Rosa A, Cumba L, Boukli N, Ríos-Olivares E, Cubano LA. Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010. AIDS Res Treat. 2012;2012:934041. doi: 10.1155/2012/934041. Epub 2012 Apr 24. PMID: 22593823; PMCID: PMC3347695.
Copy Download .nbib Format: NLM
Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European expanded access programme.

International journal of antimicrobial agents

Moyle G, Goll A, Snape S, Harris R, Wilkes C, Warburg M, Salgo M.
PMID: 18611734
Int J Antimicrob Agents. 1996 May;7(1):41-8. doi: 10.1016/0924-8579(96)00008-8.

This international expanded access programme was initiated to provide zalcitabine (o 75 mg three times daily) to patients with AIDS or advanced ARC who had failed, were no longer able to tolerate or were ineligible to receive zidovudine (ZDV)....

Cite
Moyle G, Goll A, Snape S, et al. Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European expanded access programme. Int J Antimicrob Agents. 1996;7(1):41-8doi: 10.1016/0924-8579(96)00008-8.
Moyle, G., Goll, A., Snape, S., Harris, R., Wilkes, C., Warburg, M., & Salgo, M. (1996). Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European expanded access programme. International journal of antimicrobial agents, 7(1), 41-8. https://doi.org/10.1016/0924-8579(96)00008-8
Moyle, G, et al. "Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European expanded access programme." International journal of antimicrobial agents vol. 7,1 (1996): 41-8. doi: https://doi.org/10.1016/0924-8579(96)00008-8
Moyle G, Goll A, Snape S, Harris R, Wilkes C, Warburg M, Salgo M. Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European expanded access programme. Int J Antimicrob Agents. 1996 May;7(1):41-8. doi: 10.1016/0924-8579(96)00008-8. PMID: 18611734.
Copy Download .nbib Format: NLM
Determination of Zalcitabine in Medicaments by Differential Pulse Voltammetry.

Journal of pharmaceutics

Leandro KC, Moreira JC, Farias PA.
PMID: 26555981
J Pharm (Cairo). 2013;2013:495814. doi: 10.1155/2013/495814. Epub 2013 Apr 04.

The zalcitabine (ddC) has been extensively used in the treatment of HIV patients due to its antiretroviral activity. The quality control of this active principle in medications is of outstanding importance to public health. The principal objective of the...

Cite
Leandro KC, Moreira JC, Farias PA. Determination of Zalcitabine in Medicaments by Differential Pulse Voltammetry. J Pharm (Cairo). 2013;2013:495814doi: 10.1155/2013/495814.
Leandro, K. C., Moreira, J. C., & Farias, P. A. (2013). Determination of Zalcitabine in Medicaments by Differential Pulse Voltammetry. Journal of pharmaceutics, 2013495814. https://doi.org/10.1155/2013/495814
Leandro, Katia Christina, et al. "Determination of Zalcitabine in Medicaments by Differential Pulse Voltammetry." Journal of pharmaceutics vol. 2013 (2013): 495814. doi: https://doi.org/10.1155/2013/495814
Leandro KC, Moreira JC, Farias PA. Determination of Zalcitabine in Medicaments by Differential Pulse Voltammetry. J Pharm (Cairo). 2013;2013:495814. doi: 10.1155/2013/495814. Epub 2013 Apr 04. PMID: 26555981; PMCID: PMC4590814.
Copy Download .nbib Format: NLM
Evolution of Anti- Retroviral Therapy: Multiple Pills to Fixed Drug Combinations.

The Journal of the Association of Physicians of India

Pazare AR.
PMID: 27604430
J Assoc Physicians India. 2015 Aug;63(8):11-3.

INTRODUCTION: First anti-retroviral drug available for the treatment of HIV/AIDS patients was Zidovudine (AZT) in 1986.1 AZT monotherapy was the only available ART and it resulted in early resistance to AZT.2 Hence there was a need for new antiretroviral...

Cite
Pazare AR. Evolution of Anti- Retroviral Therapy: Multiple Pills to Fixed Drug Combinations. J Assoc Physicians India. 2015;63(8):11-3
Pazare, A. R. (2015). Evolution of Anti- Retroviral Therapy: Multiple Pills to Fixed Drug Combinations. The Journal of the Association of Physicians of India, 63(8), 11-3.
Pazare, Amar R. "Evolution of Anti- Retroviral Therapy: Multiple Pills to Fixed Drug Combinations." The Journal of the Association of Physicians of India vol. 63,8 (2015): 11-3.
Pazare AR. Evolution of Anti- Retroviral Therapy: Multiple Pills to Fixed Drug Combinations. J Assoc Physicians India. 2015 Aug;63(8):11-3. PMID: 27604430.
Copy Download .nbib Format: NLM
Zidovudine (ZDV) and Lamivudine (3TC) Combination Therapy for HIV Infection - A Review.

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

Navarrete MS, Castelo A.
PMID: 11101905
Braz J Infect Dis. 1998 Feb;2(1):1-9.

The current state of knowledge regarding the treatment of HIV infection supports the use of antiretroviral agents in such a way as to maximize the likelihood of viral suppression for as long as possible. This goal is more likely...

Cite
Navarrete MS, Castelo A. Zidovudine (ZDV) and Lamivudine (3TC) Combination Therapy for HIV Infection - A Review. Braz J Infect Dis. 1998;2(1):1-9
Navarrete, M. S., & Castelo, A. (1998). Zidovudine (ZDV) and Lamivudine (3TC) Combination Therapy for HIV Infection - A Review. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2(1), 1-9.
Navarrete, and Castelo. "Zidovudine (ZDV) and Lamivudine (3TC) Combination Therapy for HIV Infection - A Review." The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases vol. 2,1 (1998): 1-9.
Navarrete MS, Castelo A. Zidovudine (ZDV) and Lamivudine (3TC) Combination Therapy for HIV Infection - A Review. Braz J Infect Dis. 1998 Feb;2(1):1-9. PMID: 11101905.
Copy Download .nbib Format: NLM
A re-evaluation of zalcitabine.

Expert opinion on investigational drugs

Moyle G.
PMID: 15991985
Expert Opin Investig Drugs. 1998 Mar;7(3):451-62. doi: 10.1517/13543784.7.3.451.

Early in the HIV epidemic, zalcitabine (ddC) emerged as a nucleoside analogue reverse transcriptase inhibitor (NRTI) alternative to zidovudine (ZDV). However, a comparative study suggested ZDV monotherapy provided superior clinical benefit in treatment-naive patients with advanced immunodeficiency. Thus, ddC...

Cite
Moyle G. A re-evaluation of zalcitabine. Expert Opin Investig Drugs. 1998;7(3):451-62doi: 10.1517/13543784.7.3.451.
Moyle, G. (1998). A re-evaluation of zalcitabine. Expert opinion on investigational drugs, 7(3), 451-62. https://doi.org/10.1517/13543784.7.3.451
Moyle, G. "A re-evaluation of zalcitabine." Expert opinion on investigational drugs vol. 7,3 (1998): 451-62. doi: https://doi.org/10.1517/13543784.7.3.451
Moyle G. A re-evaluation of zalcitabine. Expert Opin Investig Drugs. 1998 Mar;7(3):451-62. doi: 10.1517/13543784.7.3.451. PMID: 15991985.
Copy Download .nbib Format: NLM
Human PrimPol Discrimination against Dideoxynucleotides during Primer Synthesis.

Genes

Carvalho G, Díaz-Talavera A, Calvo PA, Blanco L, Martínez-Jiménez MI.
PMID: 34680882
Genes (Basel). 2021 Sep 24;12(10). doi: 10.3390/genes12101487.

PrimPol is required to re-prime DNA replication at both nucleus and mitochondria, thus facilitating fork progression during replicative stress. ddC is a chain-terminating nucleotide that has been widely used to block mitochondrial DNA replication because it is efficiently incorporated...

Cite
Carvalho G, Díaz-Talavera A, Calvo PA, et al. Human PrimPol Discrimination against Dideoxynucleotides during Primer Synthesis. Genes (Basel). 2021;12(10)doi: 10.3390/genes12101487.
Carvalho, G., Díaz-Talavera, A., Calvo, P. A., Blanco, L., & Martínez-Jiménez, M. I. (2021). Human PrimPol Discrimination against Dideoxynucleotides during Primer Synthesis. Genes, 12(10), . https://doi.org/10.3390/genes12101487
Carvalho, Gustavo, et al. "Human PrimPol Discrimination against Dideoxynucleotides during Primer Synthesis." Genes vol. 12,10 (2021). doi: https://doi.org/10.3390/genes12101487
Carvalho G, Díaz-Talavera A, Calvo PA, Blanco L, Martínez-Jiménez MI. Human PrimPol Discrimination against Dideoxynucleotides during Primer Synthesis. Genes (Basel). 2021 Sep 24;12(10). doi: 10.3390/genes12101487. PMID: 34680882; PMCID: PMC8535229.
Copy Download .nbib Format: NLM
Line Probe Assay for Detecting Mutations in HIV-1 Reverse Transcriptase.

Methods in molecular medicine

Stuyver L, Wyseur A, Verpooten G, Rossau R.
PMID: 21331914
Methods Mol Med. 2000;24:259-67. doi: 10.1385/1-59259-245-7:259.

The human immunodeficiency virus type 1 (HIV-1) belongs to the family of positive-stranded, enveloped RNA viruses with a DNA intermediate step (retroviruses). Because of the lack of fidelity of the reverse transcriptase (RT), the replication is error-prone, and the...

Cite
Stuyver L, Wyseur A, Verpooten G, et al. Line Probe Assay for Detecting Mutations in HIV-1 Reverse Transcriptase. Methods Mol Med. 2000;24:259-67doi: 10.1385/1-59259-245-7:259.
Stuyver, L., Wyseur, A., Verpooten, G., & Rossau, R. (2000). Line Probe Assay for Detecting Mutations in HIV-1 Reverse Transcriptase. Methods in molecular medicine, 24259-67. https://doi.org/10.1385/1-59259-245-7:259
Stuyver, L, et al. "Line Probe Assay for Detecting Mutations in HIV-1 Reverse Transcriptase." Methods in molecular medicine vol. 24 (2000): 259-67. doi: https://doi.org/10.1385/1-59259-245-7:259
Stuyver L, Wyseur A, Verpooten G, Rossau R. Line Probe Assay for Detecting Mutations in HIV-1 Reverse Transcriptase. Methods Mol Med. 2000;24:259-67. doi: 10.1385/1-59259-245-7:259. PMID: 21331914.
Copy Download .nbib Format: NLM
Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: how to prevent the problem?.

International journal of antimicrobial agents

De Clercq E.
PMID: 18611816
Int J Antimicrob Agents. 1997 Jun;9(1):21-36. doi: 10.1016/s0924-8579(97)00031-9.

Of the multitude of reverse transcriptase inhibitors and protease inhibitors that have been pursued for the treatment of HIV infections, nine compounds (viz. zidovudine, didanosine, zalcitabine, stavudine, lamivudine, saquinavir, ritonavir, indinavir and nevirapine) have been approved and several others...

Cite
De Clercq E. Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: how to prevent the problem?. Int J Antimicrob Agents. 1997;9(1):21-36doi: 10.1016/s0924-8579(97)00031-9.
De Clercq, E. (1997). Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: how to prevent the problem?. International journal of antimicrobial agents, 9(1), 21-36. https://doi.org/10.1016/s0924-8579(97)00031-9
De Clercq, E. "Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: how to prevent the problem?." International journal of antimicrobial agents vol. 9,1 (1997): 21-36. doi: https://doi.org/10.1016/s0924-8579(97)00031-9
De Clercq E. Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: how to prevent the problem?. Int J Antimicrob Agents. 1997 Jun;9(1):21-36. doi: 10.1016/s0924-8579(97)00031-9. PMID: 18611816.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 13 entries